Us TOO Presents: Prostate Cancer Pathways
Prostate Cancer Pathways Event and Webcast
VIDEO
With Presenting Experts:
Sean Sachdev, MD - Radiation Treatment Options & Potential/ Probable Side Effects
Maha Hussain, MD - Advanced Prostate Cancer & Clinical Trials
Nelson Bennett, Jr., MD - Moderator & Sexual Health After Prostate Cancer Treatment
Carmen Williams, MS, CGC - Genetics & Genomics
Shilajit D. Kundu, MD - Initial Diagnosis: Active Surveillance, Surgical Options, Potential/Probable Side Effects from Surgery
Alicia Morgans, MD, MPH - Moderator
David J. VanderWeele, MD, PhD - Molecular Testing & Bone Support
CLICK TIME FOR DIRECT LINK TO EACH SEGMENT BELOW
0:10 Intro - Chuck Strand, CEO of Us TOO
2:06 About Us TOO
4:53 Agenda
5:53 Intro to Session 1 Moderator Dr. Nelson Bennett
8:04 Dr. Nelson Bennett
8:20 Intro to Dr. Shilajit Kundu
9:04 Initial Diagnosis: Active Surveillance, Surgical Options & Side Effects
9:41 Scope of Problem
10:27 Incidence
12:41 Risk
13:19 Survival
14:00 PLCO Study of Screening
15:30 USPSTF
16:02 Chance of Localized Prostate Cancer
17:00 Risk of Dying of Prostate Cancer - Surgery v. Watchful Waiting
18:29 PROTECT Trial
19:13 USPSTF Change
19:54 Low Grade Prostate Cancer
20:46 Active Surveillance
23:46 Radical Prostatectomy
24:24 Surgery
26:10 Quality of Life After Prostatectomy - Erectile Function
27:14 Urinary Function
27:36 Bowel Symptoms
28:23 Conclusions
29:55 Intro to Dr. Sean Sachdev
30:43 Radiotherapy
32:30 History
34:46 Evolution of Treatment
36:10 Computerized MLCs (Beam Shaping)
37:18 Intensity Modulated Radiation Treatment
38:45 Arc IMRT - Volumetric Mediated Arc Treatment
40:47 Genitourinary Radiotherapy, Workflow
42:51 Stereotactic Radiotherapy, High Dose Ablative RT
44:05 GammaKnife
45:09 Computer Controlled, Frame-Free Approach
45:57 Applications
47:18 Updates
47:37 NCCN Risk Classification
48:08 Low Risk Treatment
49:15 Dose Escalation RTOG 0126
50:57 Androgen Deprivation Therapy & RT
55:22 Post-Operative Treatment, Radiotherapy
55:40 Adjuvant v. Salvage
56:07 Adjuvant RT Utilization
56:56 ADT
58:24 Androgen v. Salvage RT
1:00:15 Dr. Nelson Bennet - Prostate Cancer & the Penis
1:00:28 Post-RP Sexual Dysfunctions
1:01:01 ED After Prostatectomy
1:01:50 Anatomy
1:02:07 Nerve-Sparing Surgery
1:03:10 Radiation Therapy & ED
1:05:18 Importance of Sexual Function - Psychological Issues
1:05:48 ED & Depression
1:07:00 Erectile Function Recovery
1:09:54 Other Dysfunctions
1:10:00 Dysorgasmia
1:10:30 Orgasm-Associated Urine Leak
1:10:57 Penile Length Alterations
1:13:55 Peyronie's Disease
1:14:30 Treatments
1:14:52 Pills - Phosphodiesterase Type 5 Inhibitors
1:16:17 Vacuum Devices
1:17:20 Transurethral PGE (Muse)
1:17:50 Intracavernosal Injections
1:18:24 Penile Rehabilitation - Prophylactic Therapy
1:20:10 Surgical Options - Penile Prosthesis
1:22:12 Prosthesis - Advantages & Disadvantages
1:23:16 Intro to Cliff Whall, Us TOO Support Group Leader
1:24:29 Patient Perspective
1:43:30 Panel Discussion & Q&A
2:09:00 Intro to Sponsors
2:15:15 Intro to Session 2 Moderator - Dr. Alicia Morgans
2:17:11 Intro to Carmen Williams
2:18:54 Genetics
2:19:56 Genetic Counselors
2:21:50 Genetics 101
2:22:41 Terminology
2:23:59 How Genes Cause Cancer
2:24:33 Normal Human Genome
2:25:20 Somatic v. Germline
2:27:03 Distribution of Cancer
2:27:33 Genetics 201 - Hereditary Conditions
2:29:37 Genetic Counseling Consultations
2:30:31 When to Suspect Hereditary Prostate Cancer
2:31:45 Genes Associated with Hereditary Prostate Cancer
2:32:24 Possible Results
2:33:54 Considerations for Undergoing Genetic Testing
2:35:09 Family that is BRCA+
2:36:42 Genetic Discrimination
2:38:56 Take Home Points - Hereditary Genetic Testing
2:39:31 Genetics 301 - DNA Testing of Tumors
2:42:25 Goals of Somatic Testing
2:43:37 Results
2:44:44 Take Home Points - Somatic Tumor DNA Testing
2:45:18 Resources
2:46:52 Intro to Dr. Maha Hussain
2:48:53 Prostate Cancer Disease States
2:52:08 Metastatic Prostate Cancer
2:54:42 Hypothalamic-Pituitary-Gonadal Axis
2:55:20 Historical Perspective: Androgens & Prostate Cancer
2:56:27 Metastatic Hormone Sensitive Prostate Cancer
2:57:55 Landmarks of FDA Drug Approvals
3:01:16 Metastatic Castration Resistant Prostate Cancer Treatment Options
3:02:00 mCRPC Research Themes/Emerging Data
3:04:46 CARD Clinical Trial
3:05:28 Imaging-Based Progression-Free Survival, Estimates of Overall Survival & PFS
3:06:59 Precision Medicine
3:07:57 Genomic Landscape of SU2C Metastatic Castration Resistant Prostate Cancer
3:08:51 DNA Damage Response & PARP Inhibitors
3:09:56 PROfound Phase 3 Study of Olaparib v. Enzalutamide
3:13:27 Revisiting Chemohormonal & Combined Androgen Deprivation Strategies
3:14:02 CHAARTED
3:15:05 LATITUDE
3:15:40 ENZAMET
3:16:14 Metastatic Hormone Sensitive PCa
3:16:44 Prostate Cancer General Disease States
3:17:23 Non Metastatic Castration-Resistant Prostate Cancer
3:18:18 Demographic & Disease Characteristics at Baseline
3:18:36 Metastasis-Free Survival
3:19:33 Prostate Cancer Survival Over Time
3:21:03 Conquer Prostate Cancer Through Research & Excellence in Care
3:22:02 Dr. Alicia Morgans - Intro to Dr. David J. VanderWeele
3:23:28 Oncology
3:24:52 Why Consider Genomic/Molecular Testing
3:29:38 Homologous Recombination Pathway
3:33:47 Mismatch Repair Pathway
3:44:10 Bone Strength
3:47:16 Risk for Fractures
3:48:20 How Can You Prevent Fractures
3:50:21 Panel Discussion & Q&A
Thank You to Host: Northwestern Medicine, Robert H. Lurie Medical Research Center and Sponsors: Astellas, Pfizer Oncology, Amgen, Genomic Health, Clovis Oncology, Dendreon, Advanced Accelerator Applications, Foundation Medicine, Sanofi Genzyme, and Timm Medical Technologies Inc.
